AVTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AV

Mkt Cap

$604.4M

Volume

793.06K

Next Earnings

November 5th

Loading chart

AV

AVTXAvalo Therapeutics, Inc. Common Stock

AVTX

Pay with—

Available Balance0.00

AV

Mkt Cap

$644.1M

Volume

793.06K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Avalo Therapeutics to Join the Russell 2000® and Russell 3000® IndexesAvalo Therapeutics, a clinical-stage biotech company focused on IL-1β pathway therapeutics, announced its inclusion in the Russell 2000 and Russell 3000 indexes effective June 26, 2026. The company's lead asset abdakibart, an anti-IL-1β monoclonal antibody, recently reported positive Phase 2 data in hidradenitis suppurativa, with plans to advance next-generation candidate AVTX-010.GlobeNewswire Inc. · Jun 26, 2026

Avalo Therapeutics Announces Pricing of $375 Million Public OfferingAvalo Therapeutics priced an underwritten public offering of 19.73 million shares at $17.75 per share and 1.4 million pre-funded warrants, expected to raise approximately $375 million in gross proceeds. The company plans to use the funds to advance clinical development of its lead asset abdakibart, including Phase 3 topline data release, following positive Phase 2 results in hidradenitis suppurativa. The offering is expected to close on May 7, 2026.GlobeNewswire Inc. · May 6, 2026

Avalo Therapeutics to Participate in Upcoming Investor ConferencesAvalo Therapeutics, a clinical-stage biotech company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, announced that management will participate in two investor conferences in February 2026: the Guggenheim Emerging Outlook Biotech Summit on February 11 and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25. The company's lead asset, AVTX-009, is currently in Phase 2 clinical trials for hidradenitis suppurativa.GlobeNewswire Inc. · Feb 4, 2026

Hidradenitis Suppurativa Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 24+ Companies and 26+ Therapies | DelveInsightA comprehensive analysis reveals a robust pipeline for hidradenitis suppurativa treatment, with 24+ companies developing 26+ therapies, focusing on innovative biologic and targeted approaches like IL-17 and JAK inhibitors to address significant unmet clinical needs.GlobeNewswire Inc. · Oct 23, 2025

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving PremarketMerus NV shares jumped 38.2% in pre-market trading after Genmab announced plans to acquire the company for $8 billion in an all-cash deal, adding breakthrough therapy Petosemtamab to its late-stage pipeline.Benzinga · Sep 29, 2025

Avalo Therapeutics Appoints Kevin R. Lind to Board of DirectorsAvalo Therapeutics announced the appointment of Kevin R. Lind to its Board of Directors, bringing over 20 years of leadership experience in biotechnology and capital markets. Lind previously led Longboard Pharmaceuticals to a $2.6 billion acquisition and will support Avalo's development of AVTX-009 for hidradenitis suppurativa.GlobeNewswire Inc. · Sep 22, 2025

Avalo Therapeutics to Participate in Upcoming Investor ConferencesAvalo Therapeutics announced participation in three investor conferences in September 2025, highlighting their lead asset AVTX-009, a monoclonal antibody targeting IL-1β for treating inflammatory diseases.GlobeNewswire Inc. · Aug 27, 2025

Avalo Therapeutics to Participate in Upcoming Investor ConferencesAvalo Therapeutics, a clinical-stage biotechnology company, announced its participation in upcoming investor conferences to discuss its lead asset AVTX-009, a monoclonal antibody targeting inflammatory diseases.GlobeNewswire Inc. · Jun 23, 2025

Avalo Reports First Quarter 2025 Financial Results and Recent Business UpdatesAvalo Therapeutics announced progress in its Phase 2 LOTUS trial for hidradenitis suppurativa, with topline data expected in 2026. The company has sufficient cash runway into 2027, with potential to extend into 2028. Avalo is carefully evaluating the timing of additional development activities to preserve capital.GlobeNewswire Inc. · May 12, 2025

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy OfficerAvalo Therapeutics, a clinical-stage biotechnology company, has appointed Jennifer Riley as its new Chief Strategy Officer. Riley brings extensive experience in the biotechnology and pharmaceutical industries, and will oversee corporate strategy, commercial and product pipeline planning to drive growth and innovation at Avalo.GlobeNewswire Inc. · Jan 2, 2025

to start trading

AV

AVTXAvalo Therapeutics, Inc. Common Stock

AVTX

Pay with—

Available Balance0.00

Your PositionYou don't own any AVTX yet.

Related Tickers

Earnings